,Canonical_Smiles,drug_name,drug_type,Label
0,CCC(N)Cc1ccc2c(c1)OCO2,BDB,2D6-Substrate,negative
1,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,positive
2,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
3,CCOC(=O)C1(c2ccccc2)CCN(C)CC1,meperidine,2D6-Substrate,negative
4,CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,Delapril,-,negative
5,COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12,Abecarnil,-,negative
6,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,Bicalutamide,2D6-Inhibitor,negative
7,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
8,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,Nilutamide,-,negative
9,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C,Lacidipine,-,negative
10,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)C=CC=CC[C@@H](C)OC(=O)C[C@H]1O,Spiramycin,3A4-Substrate,negative
11,COc1ccc(OC(F)(F)F)cc1CN,cp_677_623,2E1-Substrate,negative
12,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H]1CCC(=O)N1,Buserelin,19A-Inducer,negative
13,C[C@@](N)(Cc1ccc(O)c(O)c1)C(=O)O,Methyldopa (levorotatory),GST-Inhibitor,negative
14,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer,negative
15,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Adenosine,Sodiumbile_acid_cotransporter-Inducer,negative
16,N[Pt](N)(Cl)Cl,Cisplatin,Probable_low_affinity_copper_uptake_protein_2-Substrate,negative
17,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Troleandomycin,CP2CI-Inhibitor,negative
18,CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@@H](CO)c1ccccc1)C2,Atropine,1A2-Inhibitor,positive
19,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,Sertindole,2D6-Substrate,negative
20,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
21,CCCC1(CCc2ccccc2)CC(O)=C(C(CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,Tipranavir,-,negative
22,COCCCOc1ccnc(CC(=O)c2nc3ccccc3[nH]2)c1C,Rabeprazole,-,negative
23,c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,Bifonazole,19A-Inhibitor,negative
24,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
25,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5,Buprenorphine,1A2-Inhibitor,positive
26,CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1,Propafenone,1A2-Inhibitor,positive
27,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2,aflatoxin_B1,1A2-Substrate,negative
28,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,Chlorpropamide,2C19-Substrate,negative
29,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole_R,2C19-Substrate,negative
30,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,Vernakalant,2D6-Substrate,negative
31,CCCCCN(C)N=O,N_amyl_N_methyl_nitrosamine,2E1-Substrate,negative
32,ClC=C(Cl)Cl,Trichloroethylene,2E1-Substrate,negative
33,CCN(CC)C(=S)[S-].[Na+],Ditiocarb sodium,-,negative
34,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Betamethason,19A-Inducer,negative
35,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,Loperamide,2D6-Substrate,negative
36,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,negative
37,c1ccccc1,Benzene,-,negative
38,CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Chlorcyclizine,Multidrug_resistance_associated_protein_1-Substrate,negative
39,CC(=O)N[C@H](CS)C(=O)O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer,negative
40,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
41,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,Bromazepam,2E1-Inhibitor,negative
42,Cc1ccccc1,toluene,2E1-Substrate,negative
43,CCCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(=O)CC,Rokitamycin,-,negative
44,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,Sulfamethoxazole,-,negative
45,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,Benazepril,Aldosterone_synthase_ALDOS_Aldosterone_synthesizing_enzyme_Steroid_18_hydroxylase-Inhibitor,negative
46,CC1=CC(=O)[C@@H]2C[C@H]1C2(C)C,Levoverbenone,2B6-Substrate,negative
47,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,Ascorbic Acid (vit C),GST-Inhibitor,negative
48,CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,Clofazimine,-,negative
49,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-,negative
50,CC1COC2(c3ccccc3Cl)c3cc(Cl)ccc3NC(=O)CN12,Mexazolam,-,negative
51,CC(C)c1nc(CN(C)C(=O)N[C@@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,Ritonavir,1A2-Inhibitor,positive
52,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
53,C[C@@H](O)C(=O)O,Milchs√§ure,Monocarboxylate_transporter_1-Substrate,negative
54,CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1,diuron,2E1-Substrate,negative
55,COc1ccc2c(c1)c(CC(=O)NCC(O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,2_hydroxy_indomethacin_phenethylamide,2D6-Substrate,negative
56,Nc1ccc(O)c(C(=O)O)c1,Mesalazine,Methyltransferase-Inhibitor,negative
57,CC(C)Cn1cnc2c(N)nc3ccccc3c21,Imiquimod,-,negative
58,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,Pentamidine Isethionate,2D6-Substrate,negative
59,O=C(O)COc1ccc(C(=O)c2ccsc2)c(Cl)c1Cl,tienilic_acid_deriv_3_isomer,2C9-Substrate,negative
60,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Cortisol,-,negative
61,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,Ziprasidone,P450_HFLA-Substrate,negative
62,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,Lopinavir,1A2-Inhibitor,positive
63,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Irbesartan,1A2-Inhibitor,positive
64,COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,Alfuzosin,3A4-Substrate,negative
65,c1ccc2c(c1)Sc1ccccc1N2C[C@@H]1CN2CCC1CC2,mequitazine,2D6-Substrate,negative
66,NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1,Diclofenamide,2C9-Inducer,negative
67,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,Naproxen,SUL-Inhibitor,negative
68,c1cnc2cc3c(cc2n1)[C@H]1CNC[C@@H]3C1,Varenicline,Methyltransferase-Inhibitor,negative
69,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
70,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1=O,9_alpha_fluoro_androstadienedione,3A4-Substrate,negative
71,Oc1ccccc1-c1ccccc1,O_phenylphenol,2E1-Substrate,negative
72,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,Desloratadine,1A2-Inhibitor,positive
73,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
74,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,Teicoplanin,SUL-Substrate,negative
75,NC[C@@H](O)c1ccc(O)c(O)c1,Norepinephrine,1A2-Inhibitor,positive
76,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Ropivacaine,2D6-Substrate,negative
77,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,Chlorambucil,GST-Inducer,negative
78,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,negative
79,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,4A11-Substrate,negative
80,COc1ccc2c3c([nH]c2c1)C(C)=NCC3,harmaline,2D6-Substrate,negative
81,O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-],Trospium chloride,-,negative
82,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,Quetiapine,P450_HFLA-Substrate,negative
83,NNc1nnc(NN)c2ccccc12,Dihydralazine,1A2-Inhibitor,positive
84,COc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_methoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
85,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C[C@H]2C=Nc3ccccc32)NC[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN3CCN(CC(=O)O)CC(=O)O[In](OC(=O)C3)OC(=O)C2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Indium (111In) Pentetic Acid,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
86,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
87,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,Rivastigmine,2D6-Inhibitor,negative
88,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,Barnidipine,2D6-Inhibitor,negative
89,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
90,CN1CCN(CCCN2c3ccccc3Sc3ccccc32)CC1,Perazine,1A2-Inhibitor,positive
91,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,Duloxetine,2D6-Substrate,negative
92,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
93,CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Hydroxychloroquine,2D6-Inhibitor,negative
94,N#Cc1nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(N)c1[S@](=O)C(F)(F)F,fipronil,2C19-Substrate,negative
95,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,Pemetrexed,Proton_coupled_folate_transporter-Substrate,negative
96,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,1A2-Inhibitor,positive
97,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
98,O=[N+]([O-])OC1COC2C(O[N+](=O)[O-])COC12,Isosorbide dinitrate,-,negative
99,COc1ccc2c(CN(C)C)cc(=O)oc2c1,DiMMAMC,2D6-Substrate,negative
100,NC(=O)NO,Hydroxycarbamide,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
101,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
102,C[C@@H]1Cc2c(Cl)cc(C(=O)N[C@@H](Cc3ccccc3)C(=O)O)c(O)c2C(=O)O1,ochratoxin_A,2C9-Substrate,negative
103,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor,negative
104,Clc1cccc(Cl)c1NC1=NCCN1,Clonidine,19A-Inducer,negative
105,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C,Physostigmine,Methyltransferase-Inhibitor,negative
106,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,Tubocurarine,Methyltransferase-Inhibitor,negative
107,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,Buflomedil,2D6-Substrate,negative
108,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,Mepyramine,2D6-Inhibitor,negative
109,CCCO,Propanol,-,negative
110,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Pilsicainide,-,negative
111,C=CCc1ccccc1OC[C@@H](O)CNC(C)C,Alprenolol,2D6-Substrate,negative
112,CC(C)(C(=O)c1cccnc1)c1cccnc1,Metyrapone,2E1-Inhibitor,negative
113,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
114,Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,Flucloxacillin,-,negative
115,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,Dutasteride,-,negative
116,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1,Cefaclor,Solute_carrier_family_22_member_6-Inhibitor,negative
117,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,Docetaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
118,NCCS,Mercaptamine,GST-Inhibitor,negative
119,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,Pentoxyverine,2D6-Substrate,negative
120,NNC(=O)c1ccncc1,Isoniazid,1A2-Inhibitor,positive
121,Cc1ccnc(NC(=O)[C@H](C)c2cccc(C(=O)c3ccccc3)c2)c1,Oxatomide,2D6-Inhibitor,negative
122,CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Cypermethrin,1A2-Substrate,negative
123,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,Fingolimod,4F2-Substrate,negative
124,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
125,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3OC5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,etoposide,2E1-Substrate,negative
126,CCC[C@@H](C)[C@@]1(CC)C(=O)N=C(S)NC1=O,Thiopental,2E1-Inhibitor,negative
127,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer,negative
128,Fc1cccc(CCN2CCN(CCCc3c[nH]c4ccc(-n5cnnc5)cc34)CC2)c1,L_775_606,2C8-Substrate,negative
129,Cc1ccccc1C(OCCN(C)C)c1ccccc1,Orphenadrine,2D6-Substrate,negative
130,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
131,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,Tobramycin,N_acetyltransferase-Substrate,negative
132,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,Cladribine,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
133,CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,Mesoridazine,2D6-Substrate,negative
134,CCCCCCCC(C)O,2_nonanol,2E1-Substrate,negative
135,CON=CC1=CCCN(C)C1,Milameline,2D6-Substrate,negative
136,C1CNCCN1,Piperazine,2D6-Substrate,negative
137,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,Desvenlafaxine,2D6-Substrate,negative
138,OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(Cl)cc32)CC1,Zuclopenthixol,2D6-Substrate,negative
139,C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1,bupropion,2E1-Substrate,negative
140,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Methyltestosterone,19A-Inducer,negative
141,CCCCCCCCCCCCCCCCCC(=O)O,stearic_acid,2E1-Substrate,negative
142,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Medroxyprogesterone,-,negative
143,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Acarbose,2E1-Inducer,negative
144,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1c1cccc([N+](=O)[O-])c1,Nitrendipine,P450_HFLA-Substrate,negative
145,CC(Cc1ccccc1)N(C)Cc1ccccc1,Benzfetamine,-,negative
146,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,Azatadine,-,negative
147,CCN(C)C=O,N_methyl_ethyl_formamide,2E1-Substrate,negative
148,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifaximin,3A4-Inducer,negative
149,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,Irinotecan,P450_HFLA-Substrate,negative
150,C=CCC1([C@H](C)CCC)C(=O)NC(=O)NC1=O,Secobarbital,-,negative
151,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
152,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,cisapride,2C8-Substrate,negative
153,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,-,negative
154,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,Levofloxacin,1A2-Inhibitor,positive
155,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
156,OCc1cccnc1,Nicotinyl Alcohol (pyridylcarbinol),Coumarin_7_hydroxylase-Substrate,negative
157,CCCCCCCCCCCC(=O)O,lauric_acid,2E1-Substrate,negative
158,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,Clemastine,2D6-Inhibitor,negative
159,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,2D6-Substrate,negative
160,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O,ABT_761,2E1-Substrate,negative
161,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
162,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,Sultiame,N_acetyltransferase-Inducer,negative
163,Cc1ccc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)nc1,Glipizide,-,negative
164,NC(=O)CC[C@H](N)C(=O)O,Levoglutamide,Neutral_amino_acid_transporter_B0-Substrate,negative
165,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
166,CCOc1ccc2ccc(=O)oc2c1,7_ethoxy_coumarin,2E1-Substrate,negative
167,ClC(Cl)Cl,Chloroform,2E1-Substrate,negative
168,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
169,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,Nefazodone,P450_HFLA-Inhibitor,negative
170,CN(C)CCC=C1c2ccccc2COc2ccccc21,Doxepin,GST-Inhibitor,negative
171,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
172,Nc1nc2c(ncn2COCCO)c(=O)[nH]1,Aciclovir,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
173,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,Clotiazepam,CP2CI-Substrate,negative
174,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,Rifabutin,-,negative
175,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,taxol,2C8-Substrate,negative
176,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,Sildenafil,2E1-Inhibitor,negative
177,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
178,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,Chlordiazepoxide,2D6-Substrate,negative
179,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
180,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
181,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,1A2-Inhibitor,positive
182,CCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Ethylmorphine,P450_HFLA-Substrate,negative
183,CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,Tiotixene,2D6-Inhibitor,negative
184,CN(C)N/N=C1\N=CN=C1C(N)=O,dacarbazine,2E1-Substrate,negative
185,CN[C@@H](C)Cc1ccccc1OC,Methoxyphenamine,2D6-Substrate,negative
186,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Sorbitol,1A2-Inhibitor,positive
187,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
188,CC[C@@]1(c2ccccc2)C(=O)NC(=O)N(C)C1=O,Methylphenobarbital,-,negative
189,NNCCc1ccccc1,Phenelzine,P450_HFLA-Inhibitor,negative
190,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,Ipriflavone,1A2-Inhibitor,positive
191,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,Finasteride,GST-Inhibitor,negative
192,CC(=O)c1cc2ccccc2s1,2_acetylbenzothiophene,2E1-Substrate,negative
193,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
194,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
195,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
196,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Mometasone,2C8-Inhibitor,negative
197,O=P([O-])([O-])O,[32P]Natriumphosphat,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate,negative
198,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate,negative
199,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Indoramin,2D6-Substrate,negative
200,CC(C)(C)NCC(O)COc1ccccc1C#N,Bunitrolol,2D6-Substrate,negative
201,CN1C(=O)OC(C)(C)C1=O,Trimethadione,2E1-Substrate,negative
202,CCOP(=S)(OCC)SCCSCC,disulfoton,2D6-Substrate,negative
203,COc1ccc2c(c1)c(CC(=O)NCCc1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,indomethacin_phenethylamide,2D6-Substrate,negative
204,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,Flutamide,1A2-Inhibitor,positive
205,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12,Corticosterone,-,negative
206,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan,2C9-Substrate,negative
207,CC[C@H](C)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN)[C@H](C)CC)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)c1ccc(OS(=O)(=O)O)cc1,Pancreozymin (cholecystokinin),Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
208,NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,Nitrofural,2D6-Substrate,negative
209,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,Mizolastine,2E1-Inhibitor,negative
210,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
211,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
212,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digitoxin,SUL-Substrate,negative
213,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,-,negative
214,COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(C)CC3,dextromethorphan,2C9-Substrate,negative
215,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,Tenoxicam,-,negative
216,C[C@H]1[C@@H]2CC[C@H](C)[C@H]3CC[C@]4(C)OO[C@]23[C@@H](O[C@@H]1OC(=O)CCC(=O)O)O4,Artesunate,-,negative
217,C[C@H](CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21,Oxomemazine,-,negative
218,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,-,negative
219,OCCSCCCCCCCCCCSCCO,Tiadenol,UGT-Inducer,negative
220,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,Emedastine,-,negative
221,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@@H]4[C@H](CC[C@]3(O)C2)[C@@]2(O)CC[C@H](C3=CC(=O)OC3)[C@@]2(C)C[C@H]4O)[C@H](O)[C@H](O)[C@H]1O,G-strophanthin,Multidrug_resistance_associated_protein_1-Inducer,negative
222,CCC(=O)O[C@@H](O[P@@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,Fosinopril,Solute_carrier_family_15_member_2-Substrate,negative
223,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
224,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,Flunitrazepam,-,negative
225,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,1A2-Inhibitor,positive
226,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,Betaxolol,2D6-Substrate,negative
227,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,Mitomycin,1A2-Inducer,negative
228,Nc1nc([O-])c2c(n1)NCC(CNc1ccc(C(=O)NC(CCC(=O)[O-])C(=O)O)cc1)N2C=O.[Ca+2],Calcium folinate,-,negative
